A PYMNTS Company

US: Celgene to pay Mylan $62M to resolve cancer drug antitrust case

 |  July 31, 2019

Mylan announced Celgene will pay it US$62 million to resolve a lawsuit alleging the drugmaker improperly stifled competition for its cancer treatment drugs Thalomid and Revlimid by preventing generic versions from entering the market.

Mylan disclosed the settlement in a filing with the US Securities and Exchange Commission on Monday, July 29, days after Celgene agreed to pay US$55 million to resolve a related class action lawsuit in federal court in Newark, New Jersey.

Full Content: Reuters

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.